A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 46
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DF
Long Form : defibrotide
No. Year Title Co-occurring Abbreviation
2021 Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. COVID-19
2021 Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender. ECM, NI-SIRS
2020 Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of Turkish hematology research and education group (ThREG). allo-HSCT, HR, HSOS, SR, ThREG
2020 Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? : Prospective evaluation of pediatric EBMT criteria for VOD. HSCT, VOD
2020 The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. ECs, PI
2020 Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide. ALT, CR, HSCT, TIPS, VOD/SOS
2019 Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide. aGVHD, EC, vWF
2019 Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. CKD
2018 Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. HSCT, rhTM, SOS
10  2018 Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL. Bcl-xL, JAK2, STAT3
11  2017 Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation. HSCT, TRM, VOD
12  2016 Defibrotide in the treatment of hepatic veno-occlusive disease. HSCT, SOS, VOD
13  2016 Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation? aGVHD
14  2016 What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. ECs
15  2013 Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. CsA, ECM, HSCT, ICAM, MGV, SIR, TAC
16  2012 Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review. HSCT, RCT, VOD
17  2012 Drug safety evaluation of defibrotide. SCT, SOS, sVOD, VOD
18  2011 Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells. DVT, ECs, MM, PAI-1, tPA
19  2011 Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. EC, P.f.-GPI
20  2010 Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. HSCT, Pre
21  2009 Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. HSCT, VOD
22  2009 Use of defibrotide in the treatment and prevention of veno-occlusive disease. VOD
23  2008 Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. bFGF, HMEC-1, MOF, sVOD, VEGF
24  2008 Early complications following haematopoietic SCT in children. HC, HSCT, TAM, VOD
25  2007 Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. ---
26  2007 Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. SCT, VOD
27  2007 Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. HSCT, SOS, VOD
28  2007 Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. SOS
29  2006 Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. LPS, TF, VOD
30  2006 Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. AML, AST, GGT, GO, SOS
31  2006 Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. ATIII, HSCT, VOD
32  2006 Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. MIOP, SCT, VOD
33  2005 Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity. F-Ara, HMEC, SCT
34  2005 Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. HSCT, tPA, VOD
35  2003 Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. CR, HSCT, VOD
36  2003 Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. ECs, TF, VOD
37  2003 Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). PAI-1, SCT, VOD
38  2003 Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. MIOP, NO, PAH, SCT, VOD
39  2002 Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. MOF, PAI-1, SCT, VOD
40  2001 Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. CI, CR, MOF, SCT, VOD
41  2001 Tissue factor pathway inhibitor release induced by defibrotide and heparins. LMWHs, TFPI, UFH
42  1999 Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. ---
43  1998 Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. SCT, tPA, VOD
44  1993 Immunosuppressive effects of defibrotide. ---
45  1992 [The postoperative prevention of deep venous thrombosis and pulmonary embolism with defibrotide versus heparin-calcium: a randomized clinical multicenter study of 1296 patients undergoing major abdominal surgery]. CH, DVT, PE
46  1991 Effects of defibrotide on renal function and urinary prostanoid excretion in ciclosporin-treated rats. Ccr, CS, PGE2, TXB2